ReviewPharmaceuticals (Basel, Switzerland)2016
Heparin: Past, Present, and Future.
Review in Pharmaceuticals (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 1 synthesis or guideline pooled it, 271 citations in OpenAlex.
- Low molecular weight heparin decreases mortality and major complication rates in moderately severe and severe acute pancreatitis-a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Association between autonomic nervous dysfunction and cellular inflammation in end-stage renal disease.BMC cardiovascular disorders · 2016Trial
- PK-Informed Microphysiological Systems: From Dynamic Dosing to Quantitative In Vitro-In Vivo Translation.Pharmaceutics · 2026Review
- Dextran sulfate restores endotoxin detectability in human serum.Analytical and bioanalytical chemistry · 2026Article
- A long-wavelength tetraphenylethylene-derived fluorescent probe for sensitive detection of heparin and protamine.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Review
- Fully Synthetic Non-Carbohydrate Heparin Mimetics-Perspectives for Therapeutic Anticoagulation and Beyond?Archiv der Pharmazie · 2026Review
- Direct protamine activation of human mast cells is MRGPRX2-dependent and is modulated by heparin.The Journal of pharmacology and experimental therapeutics · 2026Article
- Modified Chitosan-Based Hemostatic Dressings Incorporating Heparin-Loaded Nanoparticles for Enhanced Hemostatic Activity.Pharmaceutics · 2026Article
- Antithrombotic Polymers: A Narrative Review on Current and Future Strategies for Their Design, Synthesis, and Application.International journal of molecular sciences · 2026Review
- Various Ways to Be Negative: Biophysical Characterization of Polyanionic Biomolecules.The journal of physical chemistry. B · 2026Article
- Sulfated Polysaccharides in Wound Healing: From Bioactive Materials Design to Regenerative Therapeutics.International journal of nanomedicine · 2026Review
- Sterile injectable products shortage in Saudi Arabia: a survey-based cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
- Benchmark of Available Explicit Solvent Models in CHARMM36m to Characterize Glycosaminoglycans.The journal of physical chemistry. B · 2025Article
- Bioactive Polysulfate-Based Nano-Assemblies Against Virus Infection.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- The Efficacy of Heparin and Nitroglycerin in Managing Vascular Embolism Complications from Polycaprolactone (PCL) Fillers: A Clinical Study.Aesthetic plastic surgery · 2025Article
- Systemic heparin administration impairs lung development in neonatal mice.Scientific reports · 2025Article
- TEG® 6s coagulation testing with a novel heparin neutralization cartridge: Technical validation and determination of normal reference ranges.American journal of clinical pathology · 2025Article
- Observational
- Unfractionated heparin may improve near-term survival in patients admitted to the ICU with sepsis attributed to pneumonia: an observational study using the MIMIC-IV database.Frontiers in pharmacology · 2025Article
- Heparin Differentially Regulates the Expression of Specific miRNAs in Mesenchymal Stromal Cells.International journal of molecular sciences · 2024Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Heparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007-2008 increased the impetus to provide non-animal-derived sources of heparin, produced under cGMP conditions. In addition, recent studies suggest that heparin may have significant antineoplastic activity, separate and distinct from its anticoagulant activity, while other studies indicate a role for heparin in treating inflammation, infertility, and infectious disease. A variety of strategies have been proposed to produce a bioengineered heparin. In this review, we discuss several of these strategies including microbial production, mammalian cell production, and chemoenzymatic modification. We also propose strategies for creating "designer" heparins and heparan-sulfates with various biochemical and physiological properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.